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Abstract
The forthcoming post-Millennium Development Goals era will bring about new challenges in global health.
Low- and middle-income countries will have to contend with a dual burden of infectious and non-communicable
diseases (NCDs). Some of these NCDs, such as neoplasms, COPD, cardiovascular diseases and diabetes, cause much
health loss worldwide and are already widely recognised as doing so. However, 55% of the global NCD burden
arises from other NCDs, which tend to be ignored in terms of premature mortality and quality of life reduction.
Here, experts in some of these ‘forgotten NCDs’ review the clinical impact of these diseases along with the
consequences of their ignoring their medical importance, and discuss ways in which they can be given higher
global health priority in order to decrease the growing burden of disease and disability.
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Introduction
Alan D. Lopez (Figure 1).
In an era of considerable interest in global health, in
part motivated by the Millennium Development Goals,
but also inspired by demonstrable success with disease
control strategies for child survival, donors, countries
and the broader global development community are in-
creasingly asking: what’s next? Certainly, the unfinished
agenda of substantially reducing the six million child
deaths that still occur each year must remain a focus of
global health and development efforts. However, there is
now increasing recognition of the imperative not only to
keep babies alive until adolescence, but of keeping ado-
lescents alive, and healthy, into old age. Seeing global
health priorities as an ‘either/or’ dichotomy is becoming
increasingly irrelevant, and uncommon. There is much
reference made to the ‘double burden’ or, more cor-
rectly, the ‘triple burden’ (including injuries) that low-
and middle-income countries are facing. But are we, the
global health community, adapting our knowledge base,
preventive practices, health care reform and whole-of-
government strategies more broadly to cope with what
are already the leading causes of health loss, namely
non-communicable diseases (NCDs)? Are we doing
enough to reduce the significant, but largely ignored, toll
that injuries cause throughout the developing world?
Large global descriptive studies of the leading causes
of health loss in populations, such as the ongoing Global
Burden of Disease Study [1] provide comparable assess-
ments, albeit with substantial and unacceptable uncer-
tainty, of the epidemiological transition that is occurring
virtually everywhere in the developing world. They are
also able to track the very modest progress that is being
made in reducing premature death and disability from
injuries, including suicide, homicide and collective vio-
lence. Indeed, over 10% of health loss worldwide cur-
rently arises from injuries, no different to what it was
two decades ago. Meanwhile, the fraction of the global
burden of disease and injury due to NCDs, including
mental and behavioural disorders, increased from 57%
to 65%. In other words, two out of every three years of
healthy life lost on the planet are attributable to NCDs.
This is not the future; it is the reality of global health
today, and it is likely to gather pace.
While demographic factors have contributed substan-
tially to this growth, disease risk has not fallen as rapidly
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Figure 1 Alan Lopez is a Melbourne Laureate Professor and the
Rowden-White Chair of Global Health and Burden of Disease
Measurement at The University of Melbourne. He is also Director
of the Global Burden of Disease Group in the Melbourne School of
Population and Global Health.
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real prospect of rates from major vascular diseases,
chronic obstructive pulmonary disease (COPD) and can-
cers rising in men throughout the developing world dur-
ing our lifetime as the full effects of their massive uptake
of smoking some decades ago begin to be seen [2]. This
may well be compounded by the large increases in over-
weight and obesity that have occurred since the early
1980s, firstly in developed countries, and more recently
in many developing populations, leading to substantial
increases in disease burden from diabetes [3]. Under-
standably, much research and many resources worldwide
have been invested in understanding the epidemiology of
these conditions in order to guide treatment and pre-
ventive programs. But, just like the policy focus of the
past few decades on child survival, with comparatively
little attention to health loss and premature death
among adults, one might also ask whether too little at-
tention has been given in global health debates to other
NCDs that, for one reason or another, might justifiably
deserve more?
So what are these ‘forgotten NCDs’ and why do they
matter? Just as the creation of the concept (and termin-
ology) of ‘neglected tropical diseases (NTDs)’ has led to
much greater recognition, research support and pro-
grammatic response, including from institutions such as
the Gates Foundation and the World Health Organisa-
tion, might a more strategic focus on neglected NCDsengender a similar global response, and is it warranted?
The evidence would suggest it is. While neoplasms,
COPD, cardiovascular diseases and diabetes cause much
health loss worldwide, more of the global NCD burden
(55%) arises from other NCDs. These include a diverse
set of causes and conditions, but among the more im-
portant are musculoskeletal disorders, especially low
back and neck pain, depression, substance use disorders,
cirrhosis of the liver, chronic kidney disease, asthma,
various digestive diseases including peptic ulcer, anxiety
disorders, congenital anomalies and haemoglobinopa-
thies. Unlike the ‘big four’ NCDs, many of these condi-
tions cause more health loss through chronic disability
rather than premature death; arguably, preventing
chronic disability ought to be an important goal of any
health system (Figure 2).
The collection of comments in this Medicine for Glo-
bal Health forum article is a timely reminder that im-
proving population health requires a focus not only on
what is important and well-studied, but on what is im-
portant and hitherto largely overlooked. Levin and
Tonelli point to the urgent need to improve the integra-
tion of research across the biomedical and clinical sci-
ences with health systems and population-based studies
to enhance policy and patient outcomes for chronic kid-
ney disease. Peter Burney reminds us that the disease
burden from asthma is not declining very much at all,
and that health services, particularly in poor countries,
are ill-equipped to manage the case load, compounded
by a poor supply of affordable medicines. Liver cirrhosis,
long neglected as a global health priority, is another con-
dition where the etiology is well understood, but as
Jürgen Rehm points out, policy responses have been dis-
appointing, particularly in reducing alcohol consump-
tion, a leading risk factor for the disease. More broadly,
alcohol and drug use disorders are causing an increasing
share of health loss in many populations, quite apart
from the social pathologies associated with their use. As
Volkow and Koob argue in their article, a more effective
response will require a serious rethink of how health
care services are provided, with greater emphasis on
screening and improved case management.
One of the principal consequences of population
aging, namely an increase in dementia, is often at the
forefront of policy discussions about the key implications
of social, economic and health trends, but there is con-
siderable uncertainty about appropriate policy responses,
in part because the condition is not well understood. As
Ferri argues, that is changing, with recent evidence em-
phasizing the importance of primary prevention to re-
duce this growing disease burden. The lack of visibility
for sickle cell disease, as Williams points out, is in part
due to poor data, in part due to the fact it is concen-
trated in the world’s poor, yet the condition accounts for
Figure 2 (See legend on next page.)
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Figure 2 Comparison of global disease burden (in DALYs) with a focus on neglected non-communicable diseases. Pyramid: Neoplasms,
COPD, cardiovascular diseases and diabetes (the ‘big four’) lead to the highest proportion of disease burden among all NCDs. However, many
other NCDs lead to a comparable proportion of disease burden, yet do not receive as much attention as the ‘big four’. We have discussed seven
of these neglected NCDs (alcohol and substance abuse, liver cirrhosis, asthma, chronic kidney disease, Alzheimer’s and other dementias, sickle cell
disease and gout) and reviewed their disease burden. Pie chart: NCDs account for 54% of total proportion of global DALYs. Although the ‘big
four’ comprise just under half of this burden (45% of the burden of NCDs; 24.4% of the total global DALY burden) all other NCDs (i.e. the
neglected NCDs) account for 55% of the burden of NCDs; 29.6% of the total global DALY burden. Data for this infographic derived from [13]. The
figure has been prepared by BioMed Central.
Figure 3 Tom Williams is Professor of Haemoglobinopathy
Research at Imperial College London. As a clinical academic he
has been studying the epidemiology of haemoglobin disorders for
more than 20 years, both in terms of the malaria protective effects
of carrier forms and the global burden and consequences of
homozygosity, particularly in relation to sickle cell disease. Based in
Kenya for the last 15 years, he has recognised the growing importance
of sickle cell disease as the country has entered its epidemiological
transition. He co-chairs the Infectious Diseases Working Group of the
Global Sickle Cell Disease Network.
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nopathies. Even gout, though a relatively minor cause of
disease burden, is an example of a severely disabling
condition that ought, with current knowledge, be better
managed and more readily preventable, as detailed in
the article by Singh.
Collectively, this reminds us that, unlike the acute, and
largely treatable nature of communicable diseases, NCDs
are complex, diverse, and manifest their impact on
population health in different ways. Mitigating their im-
pact will require a more strategic, comprehensive and
balanced approach to NCD research, treatment and pre-
vention, beyond what has been the practice for the past
half century or so, giving greater emphasis to those con-
ditions that are major causes of health loss, and which
hitherto have been largely ignored as global health prior-
ities. So, what might public health research focus on to
accelerate the recognition of neglected NCDs as a global
health priority? In my view, four pillars of research and
knowledge translation are critical to that endeavour:
i). rapidly reduce ignorance and uncertainty about the
true disease burden from these conditions by cost-
effectively and strategically improving cause of death
and disability data collection systems;
ii). improve knowledge about the most cost-effective
strategies to reduce disease burden in different pop-
ulations, and about the most appropriate and afford-
able approaches to financing treatment and
prevention;
iii). improve knowledge and understanding of established
interventions for controlling the impact of the more
important forgotten NCDs in health care debates, and
promote targeted research on promising intervention
options where this is lacking; and
iv). raise the profile of major forgotten NCDs in national
and global health fora by developing policy relevant
forecasts of likely health, economic and social costs
of continuing to ignore them.
We should not continue to ignore or forget these NCDs.
The examples reported here suggest the need for an orga-
nized, committed and urgent response by the global health
community to reducing their disease burden everywhere.Competing interests
The author declares he has no competing interests.
Sickle cell disease: a neglected non-communicable
disease of growing global importance
Thomas N Williams (Figure 3).
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disease (SCD) [4]: despite the fact that, with early detec-
tion and an inexpensive package of basic care, the ma-
jority of those born with the condition can expect to
lead a good quality of life into late adulthood, most pa-
tients with SCD are born in resource-limited settings
(RLS) where the vast majority continue to die undiag-
nosed in early childhood [4,5]. SCD is a haemoglobin-
opathy, which results from the pathological effects of
Haemoglobin S (HbS), an abnormal form of adult
haemoglobin (HbA) that results from a mutation (βs) in
the HBB gene [5]. Most subjects with SCD are βs homo-
zygotes (sickle cell anaemia; SCA), but the condition can
also result from the co-inheritance of the βs mutation
with a range of other HBB mutations, of which the most
common are those that result in HbC and the β-
thalassaemias [5]. Despite recent promising develop-
ments, including its recognition by both the UN [6] and
the WHO [7] as a disease of major and growing import-
ance, for the most part SCD remains virtually invisible
on the global health agenda. In common with many
neglected NCDs, to a large extent this can be attributed
to three interrelated issues: the fact that its greatest bur-
den falls on the world’s poorest communities, the lack of
reliable data and inadequate political will.
Because the carrier state for SCD (sickle cell trait;
HbAS) is associated with a strong survival advantage in
malaria-endemic areas, the global burden of SCD is also
aligned to that of malaria [8]. As a consequence, the vast
majority of children with SCD are born in resource-
limited settings (RLS) (particularly sub-Saharan Africa)
where routine data are least reliable (Figure 4). With few
exceptions, diagnostic facilities are poor, early life
screening is non-existent and official statistics on health-
facility usage and cause of death are sketchy within the
RLS in which the prevalence of SCD is highest. The net
result is illustrated by the most recent Global Burden ofFigure 4 Cartogram showing the estimated number of newborns wit
babies that will be born globally, by country, between 2010 and 2050. Figu
by Dr FB Piel.Disease (GBD) Survey [9], a touchstone for policy-
makers worldwide, in which causes of death were esti-
mated from vital registration, verbal autopsy (VA),
mortality surveillance, censuses, surveys, hospitals, and po-
lice and mortuary records. Few reliable data regarding the
contribution of SCD to the mortality burden can be de-
rived from any of these sources, exemplified by the fact
that before 2012, no specific questions nor any specific
diagnostic codes for SCD were included in the standard
WHO VA tools [10]. As a result the study grossly under-
estimated global SCD-related deaths for 2010 at 28,600
(16,800–40,900) [9], a figure that should almost certainly
be 4–6 times higher [11].
Because official statistics are so poor, even basic pa-
rameters such as the global number of affected births
and SCD-specific morbidity and mortality can only be
measured using indirect approaches. For example, we re-
cently used a geostatistical model that combined data on
HbAS frequencies, overall birth rates and population
densities to estimate birth rates for SCA (which accounts
for approximately 70% of SCD) by country, concluding
that globally 312,000 (294,000 − 330,000) children were
born with SCA in 2010, half being born in just three
countries: Nigeria, the Democratic Republic of Congo
and India [12] (Figure 4). Similarly, by analyzing popula-
tion data on the age-specific prevalence of SCA, an in-
direct measure of the loss through death of subjects
with this condition, we recently concluded that current
under-5 mortality among children born with SCA in
Africa lies between 50% and 90% [4]. As for mortality,
the importance of SCD as a cause of global morbidity
has been consistently under-estimated through lack of
data. Nevertheless, despite this caveat the numbers re-
main impressive, with estimates from the most recent
GBD Survey of 5,641,000 (4,244,000–7,246,000) disabil-
ity adjusted life years lost [13] and 2,954,000 (1,957,000–
4,240,000) years lived with disability [14].h SCA by country. Cartogram showing the estimated total number of
re adapted from Figure 3 within reference [11] drawn and contributed
Figure 5 Adeera Levin is Professor of Medicine and Head of the
Division of Nephrology, University of British Columbia, in
Vancouver Canada. She is the Executive Director of the BC
Provincial Renal Agency, and President Elect of the International
Society of Nephrology.
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be considered in the context of data from the North, where
in recent years, many countries have adopted universal
screening for SCD and where most now provide compre-
hensive care for affected individuals. As a result, mortality
is now rare among children born with SCD in Europe, the
USA and the Caribbean where the majority of affected
children can expect to live a relatively normal life into their
40s and 50s [15-17]. Providing such services is within reach
in many RLS: successful pilot studies of newborn screening
have been conducted in several African countries [18] and,
in comparison to diseases of higher priority (such as HIV,
TB and malaria), the provision of basic care in specialist
clinics is not expensive [19]. If widely implemented, such
approaches could save the lives of almost ten million chil-
dren worldwide between now and 2050 [12].
So how can SCD be brought ‘out of the shadows’ [6]
of its current status as a virtually invisible NCD? Perhaps
most importantly, we need better data, without which it
will remain difficult to persuade ministries of health,
policy makers, funders and the pharmaceutical industry
to devote appropriate resources to the condition. One
essential component is better data on the birth frequen-
cies and survival of children with SCD at the micro-
epidemiological level, potentially through investigations
using large-scale sample sets collected for other reasons,
such as national surveys of micronutrient status, HIV or
malaria prevalence. Similarly, the implementation of
early-life screening would be made considerably simpler
with the development of rapid tests that would circum-
vent the lack of quality-assured diagnostic laboratories
and the logistics of returning results to patients. Better
data will lead to better advocacy for SCD at every level:
from education in schools and colleges, through to
groups of affected patients, the media, celebrities, politi-
cians, funders and health agencies internationally.
Competing interests
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Chronic kidney disease as a global health burden: the
need to integrate research and health policy
Adeera Levin (Figure 5) and Marcello Tonelli (Figure 6).
Chronic kidney disease (CKD) is increasingly acknowl-
edged as a global public health problem, affecting 1 in
10 adults in most jurisdictions [20]. CKD serves as a
multiplier of risk in all populations and has a complex
interface with other conditions (such as diabetes and
cardiovascular disease). The prevalence of risk factorsfor CKD such as low birth-weight, obesity and hyperten-
sion is increasing, and when superimposed on environ-
mental and genetic influences may serve to amplify the
rising incidence of CKD over time. In addition, there are
specific conditions (such as pregnancy, pre-eclampsia,
and acute kidney injury); and specific environments
(such as tropical regions, areas of poor sanitation) that
may promote or attenuate the progression of CKD [21].
The Lancet publication of the Global Burden of
Disease Study 2010 (GBD 2010) serves as important
milestone in understanding of population health and
disease in this century [9]. The publication highlights
the value and power of data to improve our understand-
ing of health, its determinants, and the impact of strat-
egies aimed at addressing specific health issues. Global
changes in the incidence and prevalence of key NCDs
will continue to impact the incidence of CKD. Further,
CKD may influence global metrics of health such as years
lived with disability (YLD), given the burden faced by both
non-dialysis and dialysis CKD populations [14]. In the
Figure 6 Marcello Tonelli is Professor of Medicine and
Associate Vice President (Health Research) at the University of
Calgary in Calgary, Canada. He is Past President of the Canadian
Society of Nephrology and Chair of the Research and Prevention
Committee, and council member of the International Society
of Nephrology.
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20%, and due to chronic kidney disease by 15% between
1990 and 2010, so that both rose in the ‘league tables’
of causes of death (15 to 9, and 27 to 18 respectively).
This change in the relative burden of communicable
and non-communicable diseases as drivers of mortality
in most countries parallels the profound increase in the
‘lifestyle’ driven risk factors [22]. CKD now ranks 39 glo-
bally as a cause of YLD, while diabetes and ischemic
heart disease rank 9 and 21 respectively. All of the condi-
tions display regional variability, but note the YLDs due
to CKD have increased by 20% since the 1990 report.
As infant mortality and mortality from communicable
diseases are reduced in the developing world, the disabil-
ity from NCDs will increase. Some of that disability will
be driven by CKD and all of its consequences. Identify-
ing and implementing proven strategies to address risk
factors such as hypertension, obesity, and high salt in-
take will help to reduce the burden of CKD - as demon-
strated in some parts of the world such as Asia [21].Estimates of the economic burden of CKD vary de-
pending on whether dialysis and transplant therapies are
included or excluded. Regardless, it is clear that CKD is
a key driver of the high costs associated with NCDs.
One report, using provincial data in a Canadian prov-
ince, described that of a cohort of patients with diabetes,
cardiovascular disease and CKD, in various combina-
tions: 18% of hospital costs were attributable to those
with CKD either in isolation or combined with either
DM or CVD. Thus of this high risk group comprising
7.5% of the total cluster, an annual $ 189M was spent.
This study excluded those on dialysis or with trans-
plants, and so is an underestimate of the entire burden
[23]. Others have estimated that while the end stage
renal disease population (those on dialysis or transplant-
ation) make up less than 1% of the total adult popula-
tion, they consume up to 5% of national health care
budgets [24].
The study and practice of nephrology has changed
substantially over the last 50 years. Initially nephrology
was a specialty characterized by detailed study of kidney
physiology, but has evolved in parallel with availability of
dialysis and kidney transplantation – which are no lon-
ger experimental treatments, but life-saving therapies
that benefit hundreds of thousands of people worldwide.
Advances in diagnostics, research and more integrated
approaches to care have established CKD as a prevent-
able and treatable chronic disease, with multiple co-
morbidities that are directly and indirectly related to
CKD. CKD has a dramatic impact on patients and their
families - who must live with uncertainty, depression, and
the symptoms of kidney disease. Since CKD is a global
problem, different health systems, political environments
and infrastructure have led to varied strategies and prior-
ities around the world. As an international nephrology
community, we recognize that sharing key discoveries,
best practices and methodologies is the way forward.
Interventions such as certain drugs, exercise, com-
bined specialty clinics and engagement of primary care
and patients, have been studied and shown to improve
patient outcomes. Administrative databases are used
to understand the impact of CKD on health care systems
and generate population-based estimates of disease burden.
An increasing number of investigator-initiated randomized
trials have begun to address fundamental questions about
how best to care for CKD patients - how to prevent or
delay kidney failure, when to commence dialysis treatment,
how best to treat glomerulonephritis and to prevent rejec-
tion of transplanted kidneys. As in other medical re-
searchers, kidney scientists are increasingly interested in
new translational approaches to drug development, which
may lead to the discovery of novel compounds.
A comprehensive investigative framework that includes
four pillars of research (biomedical sciences, clinical
Figure 7 Jasvinder Singh is an Associate Professor of Medicine
at the University of Alabama at Birmingham and a staff
physician at the Birmingham Veterans Affairs medical center.
He is an epidemiologist and a clinician with 14 years of experience
in treating rheumatic conditions. His research focus is health services
and outcomes research in patients with arthritis with a focus on
gout, osteoarthritis and arthroplasty. Another area of interest is
systematic reviews and meta-analyses, with a focus on Network
Meta-analyses. He is the Director of the UAB Cochrane Musculoskeletal
Group Satellite Center and serves on several national and
International organizations.
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is the key to improving the outcomes for patients with
CKD. The nephrology community has built on this frame-
work to integrate clinical care and health policy with the
CKD research agenda. There are multiple examples of
teams where clinicians, investigators and administrators
work together to improve understanding of the burden in
different environments. As an example, there are provin-
cial, national and international specific initiatives whereby
researchers, administrators and clinicians collaboratively
used data to inform decision making and track outcomes
(for example, [25-27]). The CKD PC (Chronic Kidney
Disease Prognosis Consortium) has established a rich
resource, comprising over one million people with CKD in
various stages [28]. The data is collated from interven-
tional trials, large cohort studies and administrative data
sets, and as such covers the spectrum of CKD from high
risk populations to established CKD populations. Through
robust analysis of data, this international group of re-
searchers has established estimates for the prognosis of
major events, such cardiovascular disease, hospitalizations,
infections, mortality and progression to end stage kidney
disease; and recently provided evidence to support a new
end point in clinical trials [29]. The latter will facilitate
testing of interventions.
Awareness of CKD in the global health arena will
depend on continued efforts of the clinical and research
communities. The research agenda for nephrology remains
multifaceted: the support for basic science discoveries is es-
sential to uncover novel targets and mechanisms to foster
drug or therapeutic developments. Scaling up existing ad-
ministrative, research and clinical databases (some of which
have large bio-banking platforms) will optimize the design
of clinical trials, and allow clinicians to target the highest
risk individuals. New methods for setting research prior-
ities, including the perspectives of administrators, health
policy makers, patients and their families, along with prac-
ticing clinicians, remains critical. We need new studies that
inform evidence-based public policy and assess how best to
allocate scarce resources to optimize health outcomes. Fi-
nally, there is an increasing emphasis on evaluating the best
methods for translation of research findings into practice,
so that the science reliably benefits the patients.
CKD will continue to be a major public health prob-
lem for the foreseeable future, and the most rapid
growth in disease burden will be in developing countries.
To achieve a meaningful reduction in death and disabil-
ity due to CKD, the global kidney research agenda must
encompass and integrate basic, clinical, health outcome,
and population health perspectives. The international
nephrology community is committed to this engagement
of patients, healthcare administrators and policymakers
in the research agenda. The recognition of CKD as
important in the global health and NCD agendas willimprove our ability to continue progress and sustain
focus on improving patient outcomes - across the con-
tinuum of kidney disease and its major risk factors.
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Gout: an Old disease with New windows of opportunities
Jasvinder A. Singh (Figure 7).
Gout, a common inflammatory arthritis in adults
caused by elevated levels of uric acid in the blood that
lead to joint inflammation and other manifestations
such as kidney stones, is a major public health burden
worldwide [30]. Recognized in 2640 B.C., and later de-
scribed by Hippocrates as ‘the unwalkable disease’,
gout is one of the oldest known diseases. It is also a
forgotten disease. However, in terms of its impact on
patients, high prevalence, well-known pathophysiology
and biochemical abnormality, and availability of cheap,
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in medicine.
In the course of several diseases such as diabetes, can-
cer, rheumatoid arthritis and others, there is a single
window of opportunity, where interventions in early dis-
ease can prevent future complications. In comparison,
gout has several windows of opportunities throughout
the disease course and amongst various aspects of
the disease. The incidence and prevalence of gout seems
to be increasing according to several epidemiological
studies. The Rochester Epidemiology project (REP)
showed a similar increase in the incidence of gout from
0.045% in 1977–1978 to 0.061% in 1995–1996 [31]. A
study in a health maintenance organization showed an
almost doubling of prevalence of gout and/or hyperuri-
cemia from 2% in 1990 to 4% in 1999 [32]. A study based
on National Health and Nutrition Survey (NHANES) also
found that the prevalence of self-reported physician-
diagnosis of gout increased from 2.7% in 1988–1994 to
3.9% in 2007–08 [33]. Many of these opportunities may be
missed, leading to an increased burden of gout in the face
of neglected prospects for diagnosis and treatment.
First, physicians and patients need to update their
knowledge regarding the dietary and lifestyle risk factors
for gout in order to take advantage of these windows of
opportunities. New information from well-designed epi-
demiological studies is available, which update our
knowledge of the disease (based on clinical anecdotes)
and confirm or refute previous prevalent beliefs about
gout. Higher intake of meats, seafood, alcohol (in par-
ticular beer) and sugar-sweetened soft drinks (including
fruit juices and sodas) increase the risk of gout, while
low fat dairy products, Vitamin C supplements and cof-
fee decrease the risk of gout (Figure 8). Importantly,
purine-rich vegetables and nuts do not increase the risk
of incident gout [34]. A higher intake of purine-rich
foods from animal sources (meats etc.) and alcohol in-
creases the risk of gout flares [35,36]. Since environmen-
tal factors play a big role in the risk of gout as well as
risk of gout flares, they should be one of the main
foci of gout management. Our recent work with pa-
tients shows that they are interested in discussing
these options with their providers as part of their gout
management [37,38]. Physicians can counsel patients
during their regular follow-up regarding strategies to
prevent gout and in those with gout, ways to decrease
the risk and suffering from gout flares. Therefore, this
is one key area of opportunity for both physicians and
patients.
Second is the challenge of correctly diagnosing gout.
Gout manifests as intermittent monarticular acute arth-
ritis in the early years/phase of the disease and as
chronic polyarthritis with intermittent flares in the later
years. Tophi and renal stones may accompany arthritis.The rates of joint fluid aspirate-proven diagnosis of gout
are low. Given the common involvement of great toe
and other lower extremity joints in two other common
conditions, osteoarthritis and pseudogout, a presumptive
diagnosis of gout based on a history of big toe pain and
a borderline high or higher than normal range serum
urate level is problematic (Figure 8). Documentation of
additional clinical features of acute synovitis, radio-
graphic signs of overhanging margin and punched-out
erosions typical of gout, and close attention to looking
for features of other differential diagnoses (osteoarthritis,
pseudogout and rheumatoid arthritis), will often help
in a correct diagnosis of gout. The 1977 American
Rheumatism Association (ARA) preliminary criteria for
classification of acute gouty arthritis are also commonly
used for a clinical diagnosis of gout, but are inadequate
for in-office diagnosis in about 21% of cases [39]. At-
tempts should always be made to aspirate joint/bursa/
tophus and confirm the diagnosis, since documentation of
urate crystals in synovial fluid confirms gout as a single test
and the treatment for gout is often life-long.
Third is the challenge of optimal control of serum
urate. Urate-lowering therapy (ULT), including allopur-
inol and uricosurics are generic, affordable and the most
commonly used drugs; febuxostat, a new ULT, is also
available but is more expensive. ULT helps to lower
serum urate levels, a central biochemical abnormality in
gout. Current guidelines recommend achieving target
serum urate of <6 mg/dl [40], which is achieved by at
most 33% of patients [41-43]. This is a meaningful dis-
ease target since it is associated with improved clinical
outcomes such as reduction in gout flares, regression of
tophi and lower health care costs (Figure 8) [44-46].
Achievement of this serum urate target frequently re-
quires titration of allopurinol dose, sometimes up to 900
mg/day [47], rather than a monotonic 300 mg/day dose
[48]. Physicians aiming to help gout patients avoid flares
and improve function to reap the full benefits of treat-
ment need to monitor serum urate after starting ULT
and follow a treat-to-target approach. We believe that it
is possible to achieve disease remission in many gout pa-
tients with this approach. This is a paradigm shift in
gout treatment that is likely to improve patient out-
comes. A patient-physician collaborative approach is es-
sential for this to succeed.
We have summarized briefly a few opportunities for
improving care and outcomes of gout, for which there
are several additional opportunities for interventions not
mentioned here. We are at the brink of new treatment
options for gout, a better understanding of its impact on
cardiovascular and renal disease, and better management
with existing pharmacological and non-pharmacological
treatment approaches. This is an exciting era in which
we know ever more about this ancient disease.
Figure 9 Peter Burney is Professor of Respiratory Epidemiology
and Public Health at the National Heart and Lung Institute,
Imperial College London. Until 2006 he was Chair of Public Health and
Primary Care at King’s College London. In the late 1980s he started the
European Community Respiratory Health Survey to study asthma and
allergies in adults, mostly in Western Europe. Currently he co-ordinates
the Burden of Obstructive Lung Disease Study, a study of chronic
obstructive lung disease mostly in low and middle income countries.
Figure 8 Epidemiology, diagnosis and optimal management of gout.
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Asthma: a challenge for health care providers
Peter G. J. Burney (Figure 9).
Asthma is generally defined as a reversible obstruction
of the airway and is one of the most common chronic
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ingly to signify any wheezy illness that responds to bron-
chodilators. Compared with other chronic lung diseases
it starts much younger and because the mortality is rela-
tively low and the disease tends to persist, it maintains a
high prevalence in the population.
Asthma is generally divided into allergic and non-
allergic. The relation of asthma to allergic sensitisation is
complicated. Both sensitisation and atopic diseases such
as asthma run in families, but they are not inherited in
the same way [49,50]. In childhood, asthma associated
with allergies is more persistent and tends to be more
severe. In adulthood ‘non-allergic’ asthma tends to be
more severe. In childhood allergies are less common in
low income countries, as are the atopic conditions asso-
ciated with allergies, but non-allergic wheeze is equally
common in countries at all economic levels [51]. The
prevalence of allergic sensitisation has been increasing
over the long term [52], though more recent changes in
the prevalence of atopic conditions such as asthma have
been more variable among children [53].
The International Study of Asthma and Allergies in
Childhood (ISAAC) Study was the largest global survey
of the prevalence of asthma, rhinitis and eczema involv-
ing almost 2,000,000 children in 105 countries. This
study has shown very wide variations in the prevalence
of wheezy illness, with very high rates in the English
speaking countries and Latin America and wide varia-
tions even across single continents such as Europe,
where rates fall from high levels in the northwest to low
levels in the southeast [54]. The prevalence of more se-
vere disease has a different distribution, however, with a
far higher proportion of cases being recorded as severe
in sub-Saharan Africa in particular [55].
Information on adults is more sparse and comes from
the European Community Respiratory Health Survey
(ECRHS) and the World Health Survey [56]. Although
mean prevalence is least common in middle-income
countries, the maximum prevalence recorded in the poor-
est countries is below the maximum prevalence in middle
or high income countries. Sampling decisions need to in-
form the interpretation of all these studies. For instance,
in low income countries there has been a consistent find-
ing that asthma is less common in rural areas [57-59] and
over sampling of urban populations may therefore inflate
overall estimates in low income countries.
Asthma is not a common cause of death and age-
standardised death rates fell by 42% between 1990 and
2010 from 9.0 to 5.2 per 100,000. However, the global
number of deaths fell only 9% from 380,000 to 346,000
between 1990 and 2010 [22]. The slower rate of decline
in total deaths represents the aging of the population.
Mortality from asthma increases markedly with age
and with age some patients with asthma experience amarked decline in lung function [60]. This will lead to
an increasing problem for an ageing population what-
ever changes in prevalence occur. The burden associated
with asthma is therefore likely to increase both because
of continuing urbanisation in the poorer countries and
because of the ageing of the population everywhere.
Currently there is wide variation in the relative impact
of asthma on mortality. Although asthma ranks as only
the 42nd most common cause of death globally, it is
much more highly ranked in Oceania (13th), South East
Asia (25th), South Asia (26th) and North Africa and the
Middle East (30th) than in Southern and Andean (65th
and 62nd) Latin America and Western Europe (60th).
Because asthma often has an early onset and is persist-
ent throughout life, it is a relatively important cause of
disability adjusted life years lost (DALYs), ranking 28th
globally among the causes of DALYs but 8th in Oceania,
15th in Australasia and Tropical Latin America, 18th is
South East Asia and 19th in the Caribbean [13].
The chronic nature of asthma requires continuous
care and reliable access to affordable medications. These
conditions have been set out by the Global Initiative for
Asthma (GINA) [61] together with the need to prevent
exacerbations with the use, in the first instance, of in-
haled corticosteroids. However the costs and availability
of inhaled steroids are very variable and there is a ten-
dency for these to cost more in low income countries
[62]. This leads to poor management and reliance on
emergency rooms to provide care, a wasteful and less ef-
fective method of managing the condition. In a survey of
treatment failures seen in emergency rooms in 11 coun-
tries, patients with inadequate insurance and those with-
out a consistent source of continuing medical care were
less likely to be on the recommended dose of inhaled
steroids. In addition, those without adequate steroid use
were more likely to have lost work because of asthma in
the recent past [63], demonstrating the high cost to pa-
tients and their families of inappropriate care.
Asthma is a common condition that causes considerable
morbidity and with increasing age leads to a disease that is
more difficult to manage, along with increasing mortality.
Although it is mostly not difficult to manage, along with
other chronic conditions it requires continuous care,
which traditional health services are not designed to pro-
vide. Currently the problem of inadequate health services
is compounded by a poor supply of over-priced medica-
tions. These problems are shared by other chronic condi-
tions and have common solutions including the provision
of continuous long-term care and reliable access to afford-
able, high-quality medication.
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non-communicable chronic disease
Jürgen Rehm (Figure 10).
Liver cirrhosis is an abnormal condition with irrevers-
ible scarring as a result of continuous and long-term
liver damage, which is primarily caused by excessive al-
cohol consumption, hepatitis, and non-alcoholic steato-
hepatitis. It is among the top 15 causes of death globally
and, in 2012, was estimated to have caused more than
1,000,000 deaths and more than 36,000,000 years of lives
lost to either premature death or disability.Figure 10 Jürgen Rehm, Ph.D. has been appointed the
Inaugural Chair for Addiction Policy at the Dalla Lana School of
Public Health of the University of Toronto. In addition he holds
positions at the Centre for Addiction and Mental Health (Toronto,
Canada) as Director of the Social and Epidemiological Research
Department and Head of the PAHO WHO Collaborating Centre, and
at the Institute for Clinical Psychology and Psychotherapy of the
Technical University Dresden (Germany). Dr. Rehm has published more
than 600 peer-reviewed publications in addiction research, comprising
studies in epidemiology, economics and clinical research, the latter
especially in the area of treatment evaluation. He is listed among the
ISI/Thompson Reuters most highly cited in the fields of social research
and epidemiology and has been awarded the Jellinek Award, the most
prestigious award in alcohol research. He has served as public health
consultant to many countries, and is currently member of the WHO
Expert Advisory Panel on Drug Dependence and Alcohol Problems.Global death rates due to liver cirrhosis seem to have
been quite stable over the years: the World Health
Organization (WHO) estimated and predicted 14.5 deaths
per 100,000 for the years 2000 and 2030, respectively, with
almost no variation for years in between [64,65]. However,
when standardized rates are considered, liver cirrhosis
deaths are predicted to decrease.
There are several factors that may become important
to explain trends for liver cirrhosis. A downward trend
in high income countries may be predicted to be linked
to improved clinical practices leading to lower case fatal-
ity rates [66,67], although there is not much evidence on
this, and, to give just one example, historically, case fa-
tality rates have not shown any improvement over the
time period between 1968 and 1999 in England [68]. An
upward trend may be linked to increases in alcohol con-
sumption in low- and mid-income countries as they in-
crease their economic wealth [69]. In terms of burden of
disease, most DALYs were derived from years of life lost
to mortality, that is, due to the high case fatality. However,
as indicated above, this may constitute an underestimate
for high-income countries due to the lower case fatality
and thus higher duration of living with disability.
While the overall prevalence of liver cirrhosis mortal-
ity and burden of disease seems stable, there are huge
variations by gender, age and regions [70], and they seem
to be caused by preventable risk factors. Men have consid-
erably higher rates of liver cirrhosis morality and burden of
disease, globally more than twofold the rates of women,
and highest in the men between 50 and 69 years of age.
The only exception for the higher prevalence of liver cir-
rhosis mortality and burden is the Eastern Mediterranean
region, where women have slightly higher rates; this region
also has by far the lowest alcohol consumption [71], which
is the main risk factor for liver cirrhosis.
Figure 11 gives an overview of the burden of disease of
liver cirrhosis for the year 2012 in DALYs by WHO region,
and the role of alcohol in causing this disease (data based
on [71,72]). As indicated above, alcohol consumption is
globally the most important risk factor for liver cirrhosis,
responsible for about half of the global burden (50%; men:
53%; women: 44%; [71]); other main global risk factors are
hepatitis B and C, and obesity [13,73]. Europe, especially
the Eastern European region, has the highest rate of liver
cirrhosis, with alcohol consumption a large factor (63%).
For low- and mid-income countries, hepatitis-induced
liver cirrhosis is relatively more important, with the rela-
tive impact differential between high income and other
countries being largest for hepatitis B [13,74].
The role of alcohol consumption in causing and wors-
ening the course of liver cirrhosis has been evident on
the individual level [3] and on the aggregate level in
comparisons between countries [75], or in analyses over
time [76]. It is important to understand that alcohol
Figure 11 Disability adjusted life years due to liver cirrhosis per 100,000 population in WHO regions in 2012. Afr: African region. Amr:
Americas. Emr: Eastern Mediterranean region. Eur: Europe. Sear: South East Asian Region (including India). Wpr: Western Pacific Region.
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of liver cirrhosis, independent of the original aetiology
(3), and thus abstinence is the major goal in most guide-
lines for treatment of liver cirrhosis.
Intervention studies show that a reduction of alcohol
consumption via policy interventions resulted in a
marked reduction of liver cirrhosis (for example in
Russia [77,78]). Although liver cirrhosis is a chronic dis-
ease, interventions have immediate effects, as not only
shown by the Russian experiences cited above, but also
for instance by the impact of the German seizures of al-
cohol on French mortality rates during World War II, or
the impact of prohibition in the US [75,79,80]). It may
take up to 20 years, however, before all of the effects of
interventions can be seen [81].
A sizable portion of liver cirrhosis mortality could be
reduced in the first year after implementing effective in-
terventions to reduce alcohol, such as higher taxation,
decreased availability, advertisement and marketing bans
or brief interventions and treatment [82,83], especially
among heavy drinkers [72,84]. The effect is more pro-
nounced for heavy drinkers because the risk curve for
mortality is exponential; that is, relatively more mortality
can be avoided for the same amount of reduction in
average drinking for heavy drinkers compared to light or
moderate drinkers [72,84]. Such interventions would not
only reduce liver cirrhosis rates but also other causes of
mortality such as other non-communicable diseases
(cancers, hypertensive heart disease, stroke, pancreatitis)
or injuries [71,82,84,85]. Given this situation, and given
the fact that there are proven effective interventions to
reduce alcohol consumption, we see no reason why glo-
bal liver cirrhosis rates should continue to be as high as
they are now.
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Substance use disorders: implications for global health
Nora D Volkow (Figure 12) and George Koob (Figure 13).
Substance use disorders (SUD) associated with legal
substances are two of the three leading contributing fac-
tors for global burden of disease and injury (DALYs for
tobacco: 6.3%; for alcohol: 5.5%) [9] and those associated
with illicit substances are within the top twenty factors
(DALYs 0.8%) [86]. The past 20 years has seen an in-
crease in the contribution of SUD to the global burden
of disease, mostly from alcohol (32%) and illicit drugs
(57%) [9]. Moreover, the global burden of disease attribut-
able to SUD is likely to be underestimated particularly for
illicit substances due to incomplete epidemiological data
on estimates of impactful and preventable outcomes (i.e.
injuries, violence and mental health problems) [86]. Thus,
SUV prevention and treatment would have a major impact
in improving public health globally.
The recent endorsement by the United Nations Office
on Drugs and Crime (UNODC) of addiction as a brain
disease and the recommendation that it should be
treated as a medical and public health issue rather than
a criminal justice and or moral issue highlights the role
that the healthcare system can play in the prevention
and treatment of SUD [87]. The conceptualization of ad-
diction as a brain disease reflects in part findings from
brain imaging studies and preclinical research that have
identified the brain circuits that are disrupted by drugs
(legal and illegal) and how their disruption impairs the
addicted individual’s ability to control his/her behaviour
[88]. Moreover, excessive drug and alcohol use in adoles-
cence impairs executive function and increases the vul-
nerability to SUDs in adulthood. Clinical studies have
Figure 13 George F. Koob was recently appointed Director of
the National Institute on Alcohol Abuse and Alcoholism after
30 years at The Scripps Research Institute in La Jolla California.
His research has focused on the dysregulation of the brain arousal
and stress systems that drive compulsive drug and alcohol seeking.
He has made significant contributions to our understanding of the
neurocircuitry of negative emotional states and their role
in pathophysiology.
Figure 12 Nora D Volkow is Director of the National Institute
on Drug Abuse; a position she had held since 2003. Her
research transformed the drug addiction field by providing the first
evidence for specific molecular (loss of striatal D2 receptors) and
functional (impaired frontal control circuitry) changes in brains of
addicted individuals that link to compulsivity and loss of control. She
has also made ground-breaking discoveries in the neurobiology of
ADHD and obesity.
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like other chronic diseases requires continuity of care
[89]. Because all countries have health care infrastruc-
ture, it is recommended that these healthcare systems
integrate treatment of SUD within the system norms.
Drug associated health consequences are still some of
the main preventable causes of disability and the health-
care system can play a crucial role in their prevention
and treatment. This recommendation provides a plat-
form that is relevant and available to countries with dif-
ferent levels of economic development.
Health care systems can participate at all levels in the se-
verity range of SUD, starting from its prevention to serving
as a referral for specialized care for the most severe cases.
Health care systems can also maximize the opportunity
to integrate the care for the health problems associated
with SUD. Of particular importance is the management ofmental illnesses, since they are frequently co-morbid with
SUD, and inappropriate management of either condition
exacerbates the other. Similarly, integrated care is funda-
mental for the treatment of infectious diseases such as
HIV and HCV for which substance abusers are at higher
risk and for which compliance with medical treatment of
the infectious disease requires parallel treatment of the
SUD. In addition, SUD is the main underlying cause of ve-
hicle accidents. Therefore, integrated care will also facilitate
addressing this factor, for if untreated the alcoholic or drug
abuser will continue to contribute to repeated incidents.
Moreover, in these times of increasing health care costs
and burden, treating SUD’s would translate into significant
savings in the need to treat the secondary health costs
of SUD.
The challenges in implementing healthcare involve-
ment in SUD management are complex and will vary
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sources, cultural norms, drug availability and policies to-
wards criminalization and legalization of drugs. This is
further compounded by rapid changes in the use of
drugs across the world, such as movements towards
legalization of marijuana, recent access to electronic
drug delivery devices, rapid dissemination of new syn-
thetic drugs and the increased abuse of prescription
medications. The opportunities that the healthcare sys-
tem offers towards the control of SUD highlight the ur-
gent need for educating health care providers in the
screening and management of SUD and the need to allo-
cate the resources necessary for its implementation.
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Placing dementia in the NCDs prevention strategies
Cleusa P. Ferri (Figure 14).
Dementia is a syndrome that usually involves with loss
of memory, reasoning, and other cognitive functions
progressively impairing an individual’s everyday func-
tioning. The main risk factor for dementia is age, with
prevalence roughly doubling every 5 years over the ageFigure 14 Cleusa P. Ferri is an Affiliated Professor at the
Universidade Federal de Sao Paulo in the post-graduation
program of the Psychobiology Department, supported by
Associação Fundo de Incentivo a Pesquisa (AFIP), and a Senior
Epidemiologist at the Institute of Education and Health Sciences
at the Hospital Alemao Oswaldo Cruz, Brazil. She worked as an
international specialist on dementia for the Global Burden of Disease
2010 Project. In the same capacity, she was also involved with the
MHGap project with the WHO. For 10 years Dr Ferri worked at the
Institute of Psychiatry, King's College London. During this period,
apart from her teaching and other research activities, she worked
with the 10/66 Dementia Research Group, studying the epidemiology
of dementia in low- and middle-income countries. She returned to
Brazil, her home country, in 2013 and is now focusing her work on the
epidemiology of ageing and dementia in Brazil and Latin America.of 65. Older people are likely to have multiple health
conditions. Dementia however, has a disproportionate
impact on independent living, being a major cause of
disability and dependence [90,91] among older people.
With the rapid ageing of the population worldwide, the
number of people with dementia is predicted to rise. It
is estimated that in 2010 there were 35.6 million people
with dementia, and predictions based on population age-
ing show that this figure is likely to double every 20
years, reaching 115.4 million by 2050 [92]. Most people
with dementia already live in low- and middle-income
countries (LMIC) and these same estimates predict that
by 2050 more than 70% of people with dementia will be
living in these countries [92].
It has been estimated that the total worldwide cost of
dementia was US$604 billion in 2010 [93]. While most
of these costs are concentrated in high income coun-
tries, where the costs are divided roughly equally be-
tween formal (hospital and social) and informal (family)
care settings, in low- and middle-income countries, in-
formal care costs account for the vast majority of total
costs [93], with the burden concentrated on families and
informal carers. Formal costs are likely to increase in
these countries, not only due to the increasing numbers
of people with dementia in the future, but also because
of a shift in the balance between informal and formal
care as the health care sectors develops in LMIC.
Future estimates are mostly based on population age-
ing and include the assumption that age-specific preva-
lence will be stable over time. However, some recent
studies have suggested that over the past 20 to 30 years
there has been a decline in the predicted burden of de-
mentia in high-income countries [94-97]. In the UK, for
example, a recent study [95] indicates a reduction in de-
mentia prevalence of around 20% over a 20-year period
(from 1989–1994 to 2008–11). These reductions suggest
that predicted dementia cases were perhaps avoided or
delayed by changes in the risk factors for dementia at
earlier ages, suggesting that these risks are modifiable
and dementia, to some extent, can be prevented or, at
least, the risk reduced at particular ages.
One possible explanation for the reduction in demen-
tia is the change in cardiovascular diseases and risk fac-
tors. There is growing evidence supporting a strong
and likely causal association between cardiovascular
disease (CVD) and its risk factors, and dementia [98].
Therefore, the changes seen regarding the reduction in
dementia prevalence are likely partially due to improve-
ments in service provision and disease management of
CVD, and also to changes in behaviour, with around
half of the reduction in morbidity and mortality thought
to be accounted for by primary prevention. However,
current models to estimate the impact of preventive strat-
egies on future vascular diseases do not consider the
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(NCDs), such as cardiovascular diseases, are risk factors
for dementia and many risk and protective factors for de-
mentia are the same as those for other NCDs [99]. How-
ever, most countries’ policies and prevention strategies for
NCDs do not include the prevention, or reduction of risk,
of dementia, despite some recent initiatives [99].
In low-, middle- and high-income countries, dementia
can be seen as part of normal ageing. Although demen-
tia is indeed common in the oldest age groups, it is not
an inevitable consequence of long lifespans. Increasing
awareness of dementia in society as whole, from patients
to policy/decision makers, can contribute not only to de-
creasing stigma and increasing community solidarity,
but also to improving the capacity of existing services
with evidence based approaches that can meet the needs
of older people and those with dementia. It is important
to note that awareness campaigns need to be carried out
with great care in order to avoid raising expectations
that cannot be met, and avoid leading to unintended
consequences, such as increased stigma and fear, through
use of dramatic imagery and language.
Dementia costs to individuals, families and society as a
whole will grow as the number of people with dementia
increases, and this will have an even greater impact on
LMIC, which have fewer resources and where popula-
tion ageing is happening faster than in rich countries.
Dementia should be on the public health agenda of each
country, with careful consideration given to each coun-
try’s demographic and sociocultural context, including
their own stage of the unfolding demographic and health
transitions. The impact of change to risk factor profiles
in countries is difficult to predict. However, models look-
ing at the relative impact of primary prevention in com-
parison to approaches focused more on secondary
prevention suggest that up-stream primary prevention is
likely to be the cheapest and most efficient way to
decrease the burden of dementia for future generations
[100-102], reducing the need for costly screening and
treatment regimens for established disease. It is important
to strengthen the evidence on the effectiveness of demen-
tia prevention programmes, including their timescales,
and also to ensure that dementia takes its place in NCD
policies and prevention strategies.
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